Duchenne Muscular Dystrophy Market 2019 Industry Size, Company Share And Distribution Share Data And Analysis

"The Report OpportunityAnalyzer: Duchenne Muscular Dystrophy - Opportunity and Market Analysis to 2019 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Duchenne Muscular Dystrophy Market

Duchenne muscular dystrophy (DMD) is a rare genetic disorder affecting approximately 1 in 3,500 newborn boys and is characterized by progressive muscle degeneration, loss of ambulation, and death by the late 20s. There are no marketed pharmacological therapies that are indicated for DMD. The current standard of care treatment involves generic corticosteroids which are used to marginally prolong muscle function but do not offer preventative treatment. The anticipated launch of PTC Therapeutics Translarna in 2015 in the US and 5EU, followed by the 6MM launch of Exon-skipping therapiesBioMarin/Prosensas drisapersen and Sarepta Therapeutics eteplirsen, in 2015 and 2016, respectively, are set to change the treatment landscape and drive growth in the DMD market. GlobalData estimates that the uptake of Translarna and exon-skipping therapies will be very high due to the lack of effective disease-modifying therapies for DMD. GlobalData estimates that the DMD market was valued at $8.2m across the 6MM in 2014, and it is expected to sharply increase to approximately $990.0m in 2019, at a Compound Annual Growth Rate (CAGR) of 160.5%.

Highlights

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/293897

Key Questions Answered

How will the DMD market landscape change within the 2014-2019 forecast periods in the 6MM?
What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the DMD market?
How do the clinical and commercial attributes of late-stage pipeline drugs compare to one another and against existing treatment options?
Which patient population(s) are most likely to be targeted by late-stage pipeline drugs?
What are the significant unmet needs and remaining opportunities in the DMD market?

Key Findings

Due to strong demand from patient community and clinicians, high uptake is expected of pipeline drugs for DMD that are anticipated to launch during the 2014-2019 forecast period.
Mutation-specific therapies are expected to emerge as the major R&D breakthrough and future market drivers for DMD.
With ongoing research, large pharmaceutical companies, small biotechs, and research institutions have discovered a multitude of therapeutic strategies to treat DMD. There are 19 ongoing clinical trials in DMD with 11 molecules in Phase II and eight molecules in Phase I.
The lack of consensus over clinical trial design and endpoints for the development of DMD therapies continues to be a barrier to clinical development of new drugs.
The clinical stage pipeline is mainly focussed on ambulatory DMD patients with specific mutations, leaving a large unaddressed population and vast opportunity for developers to deliver new therapies, and for continued growth in the DMD market beyond 2019.

View Full Report @ https://www.marketresearchreports.biz/reports/293897/opportunityanalyzer-duchenne-muscular-dystrophy-market-research-reports

Scope

Overview of DMD, including epidemiology, etiology, pathophysiology, symptoms and current treatment options
Annualized DMD therapeutics market revenue, annual cost of therapies and forecasts for five years to 2019.
Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the DMD therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including nonsense mutation readthrough inducer, exon-skipping therapies, synthetic electron transporter, PDE5 inhibitor.
Analysis of the current and future market competition in the US and five major EU DMD therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.

Reasons to buy

Identify the unmet needs and remaining opportunities in the DMD therapeutics market.
Develop business strategies by understanding the trends shaping and driving the US and five major EU DMD therapeutics market.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Assess the clinical and commercial viability of promising pipeline products.
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various emerging therapies.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Drive revenues by understanding the key trends, innovative products and technologies, market and segments likely to impact the US and five major EU DMD therapeutics market in future.

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/293897

Table of Contents

1 Table of Contents 8
1.1 List of Tables 12
1.2 List of Figures 15

2 Introduction 16
2.1 Catalyst 16
2.2 Related Reports 17

3 Disease Overview 18
3.1 Etiology and Pathophysiology 18
3.1.1 Etiology 18
3.1.2 Pathophysiology 19
3.2 Prognosis and Symptoms 20
3.3 Diagnosis 21

4 Epidemiology 23
4.1 Disease Background 23
4.2 Risk Factors and Comorbidities 24
4.3 Global Trends 25
4.4 Forecast Methodology 27
4.4.1 Sources Used 33
4.4.2 Sources Not Used 34
4.4.3 Forecast Assumptions and Methods 35
4.5 Epidemiological Forecast for DMD (2013-2023) 40
4.5.1 Diagnosed Prevalent Cases of DMD (All Ages) 40
4.5.2 Diagnosed Prevalent Cases of DMD (Ages 5-13 Years) 42
4.5.3 Age-Specific Diagnosed Prevalent Cases of DMD (All Ages) 44
4.5.4 Age-Standardized Diagnosed Prevalence of DMD 45
4.6 Epidemiological Forecast for Nonsense Mutations in DMD (2013-2023) 46
4.7 Epidemiological Forecast for the Applicability of Exon-Skipping Therapies in DMD (2013-2023) 48
4.7.1 Diagnosed Prevalent Cases of DMD Eligible for an Exon 51 Skipping Therapy (All Ages) 48
4.7.2 Diagnosed Prevalent Cases of DMD Eligible for an Exon 45 Skipping Therapy (All Ages) 49
4.7.3 Diagnosed Prevalent Cases of DMD Eligible for an Exon 53 Skipping Therapy (All Ages) 51
4.7.4 Diagnosed Prevalent Cases of DMD Eligible for an Exon 44 Skipping Therapy (All Ages) 52
4.8 Epidemiological Forecast for BMD (2013-2023) 54
4.8.1 Diagnosed Prevalent Cases of BMD (All Ages) 54
4.8.2 Age-Specific Diagnosed Prevalent Cases of BMD (All Ages) 55
4.8.3 Age-Standardized Diagnosed Prevalence of BMD 57
4.9 Discussion 58
4.9.1 Epidemiological Forecast Insight 58
4.9.2 Limitations of the Analysis 59
4.9.3 Strengths of the Analysis 60

5 Current Treatment Options 61
5.1 Overview 61
5.1.1 Duchenne Muscular Dystrophy 61
5.1.2 Becker Muscular Dystrophy 62
5.2 Product Profiles - Major Brands 63
5.2.1 Corticosteroids (Prednisone and Deflazacort - Numerous Generic and Brand Names) 63
5.2.2 Translarna (ataluren) 66

6 Unmet Needs Assessment and Oppportunity Analysis 72
6.1 Overview 72
6.2 Need for Disease-Modifying Therapies 73
6.2.1 Unmet Need 73
6.2.2 Gap Analysis 74
6.2.3 Opportunity 74
6.3 Delayed Diagnosis 75
6.3.1 Unmet Need 75
6.3.2 Gap Analysis 76
6.3.3 Opportunity 76
6.4 High Variation in Design of DMD Clinical Trials 77
6.4.1 Unmet Need 77
6.4.2 Gap Analysis 78
6.4.3 Opportunity 78
6.5 Need for Regulatory Pathway for Approval of Follow-On Exon-Skipping Molecules 79
6.5.1 Unmet Need 79
6.5.2 Gap Analysis 79
6.5.3 Opportunity 80

7 R&D Strategies 81
7.1 Overview 81
7.1.1 Follow-On and Multi Exon-Skipping Molecules 81
7.1.2 Forming Alliances with Patient Advocacy Groups 82
7.1.3 Partnering with Pharmaceutical Companies to Increase Marketing Resources 83
7.2 Current Clinical Trial Design 84
7.2.1 Current Methods for Assessing Clinical Efficacy and Their Limitations 85
7.2.2 Current Trial Design of Key Pipeline Products 87
7.2.3 Patient Exclusion Issues in Current Trial Designs 88
7.3 Future Clinical Trial Design 89
7.3.1 Dystrophin-Positive Biomarkers as Surrogate Clinical Endpoints 89
7.3.2 Need for Measuring Clinical Outcome and Endpoints Based on Disease Onset 90
7.3.3 Maximizing Inclusion of Patient Populations in Studies 91

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.